KYORIN Holdings Inc (4569):企業の財務・戦略的SWOT分析

GlobalDataが発行した調査報告書(DATA904C9032)
◆英語タイトル:KYORIN Holdings Inc (4569) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C9032
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:42
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

KYORIN Holdings Inc (4569) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

KYORIN Holdings Inc (KYORIN), formerly known as KYORIN Co.,Ltd., is a holding company. Its business activities include controlling, administering and supporting companies, which conduct various businesses by holding the shares of those companies. The company through its subsidiaries carries out the discovery, manufacturing and sale of pharmaceuticals including new ethical drugs, generic drugs and the over-the-counter (OTC) drugs. It also provides consumer healthcare products including beauty and good health products. KYORIN provides product under Kipres, Mucodyne, Pentasa, Uritos, Ketas, Flutiform, Milton, Rubysta and other brands. KYORIN is headquartered in Chiyoda-Ku, Tokyo, Japan.

KYORIN Holdings Inc Key Recent Developments

Sep 24,2018: Kyorin Receives Approval from Japan’s Ministry of Health, Labour and Welfare for Vibegron for Overactive Bladder
Aug 28,2018: Kyorin Receives Approval from Japan’s Ministry of Health, Labour and Welfare for Vibegron for Overactive Bladder
Jun 06,2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Kyorin
Feb 22,2017: Kyorin Holdings: Establishment of a Representative Office in the Republic of Indonesia
Feb 22,2017: Kyorin: Change of Representative Director and President at ActivX Biosciences

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
KYORIN Holdings Inc – Key Facts 6
KYORIN Holdings Inc – Key Employees 7
KYORIN Holdings Inc – Key Employee Biographies 8
KYORIN Holdings Inc – Major Products and Services 9
KYORIN Holdings Inc – History 10
KYORIN Holdings Inc – Company Statement 14
KYORIN Holdings Inc – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 – Company Analysis 16
Company Overview 16
KYORIN Holdings Inc – Business Description 17
Business Segment: Consumer Healthcare Business 17
Overview 17
Performance 17
Business Segment: Ethical Pharmaceutical Business 17
Overview 17
Performance 17
R&D Overview 18
KYORIN Holdings Inc – Corporate Strategy 19
KYORIN Holdings Inc – SWOT Analysis 20
SWOT Analysis – Overview 20
KYORIN Holdings Inc – Strengths 20
KYORIN Holdings Inc – Weaknesses 21
KYORIN Holdings Inc – Opportunities 22
KYORIN Holdings Inc – Threats 23
KYORIN Holdings Inc – Key Competitors 24
Section 3 – Company Financial Ratios 25
Financial Ratios – Capital Market Ratios 25
Financial Ratios – Annual Ratios 26
Performance Chart 29
Financial Performance 29
Financial Ratios – Interim Ratios 30
Financial Ratios – Ratio Charts 31
Section 4 – Company’s Lifesciences Financial Deals and Alliances 32
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 32
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 33
KYORIN Holdings Inc, Recent Deals Summary 34
Section 5 – Company’s Recent Developments 35
Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Kyorin 35
Feb 22, 2017: Kyorin Holdings: Establishment of a Representative Office in the Republic of Indonesia 36
Feb 22, 2017: Kyorin: Change of Representative Director and President at ActivX Biosciences 37
Section 6 – Appendix 38
Methodology 38
Ratio Definitions 38
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
KYORIN Holdings Inc, Key Facts 6
KYORIN Holdings Inc, Key Employees 7
KYORIN Holdings Inc, Key Employee Biographies 8
KYORIN Holdings Inc, Major Products and Services 9
KYORIN Holdings Inc, History 10
KYORIN Holdings Inc, Subsidiaries 15
KYORIN Holdings Inc, Key Competitors 24
KYORIN Holdings Inc, Ratios based on current share price 25
KYORIN Holdings Inc, Annual Ratios 26
KYORIN Holdings Inc, Annual Ratios (Cont...1) 27
KYORIN Holdings Inc, Annual Ratios (Cont...2) 28
KYORIN Holdings Inc, Interim Ratios 30
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 32
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 33
KYORIN Holdings Inc, Recent Deals Summary 34
Currency Codes 38
Capital Market Ratios 38
Equity Ratios 39
Profitability Ratios 39
Cost Ratios 40
Liquidity Ratios 40
Leverage Ratios 41
Efficiency Ratios 41

List of Figures
KYORIN Holdings Inc, Performance Chart (2014 - 2018) 29
KYORIN Holdings Inc, Ratio Charts 31
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 32
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 33

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ KYORIN Holdings Inc (4569):企業の財務・戦略的SWOT分析(KYORIN Holdings Inc (4569) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆